Clinical Trials

290 enrolled

Advanced Gynecological Malignancies

NCT07449481 2026-03-04

A Single-Arm, Open-Label, Phase II Clinical Study of Utidelone and Bevacizumab With or Without Etoposide in Patients With Brain Metastases From Malignant Solid Tumors

56 enrolled

Brain Neoplasms

NCT07420439 2026-02-19

Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease

108 enrolled

Lung Diseases, Interstitial

NCT07383285 2026-02-03

CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer

106 enrolled

Rectal Neoplasms Malignant

NCT07370818 2026-01-27

To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian Cancer

81 enrolled

Ovarian Neoplasms

NCT07359456 2026-01-22

COLIBRI-GI

130 enrolled

Colorectal Neoplasms

NCT07340164 2026-01-14

TROY

116 enrolled

Ovarian Neoplasms, Recurrence

NCT07337551 2026-01-13

Gossypol Acetate + FOLFIRI + Bev in mCRC With TP53-Mutant and LRPPRC Positive

20 enrolled

Colorectal Neoplasms

NCT07229846 2026-01-08

A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation

Colorectal Neoplasms

NCT07179900 2025-12-11

Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT07244926 2025-11-24

Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer

31 enrolled

Lung Neoplasms

NCT07178717 2025-09-17

REFISH

25 enrolled

Colonic Neoplasms

NCT07150403 2025-09-08

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

74 enrolled

Colorectal Neoplasms

NCT07117877 2025-08-28

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

33 enrolled

Ovarian Neoplasms

NCT07134413 2025-08-21

QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

77 enrolled

NSCLC

NCT07128251 2025-08-17

A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

47 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Hepatocellular

NCT07123441 2025-08-14

A Study on the Efficacy and Safety of Irinotecan Liposome (II), 5-FU/LV in Combination With Bevacizumab for the Treatment of Advanced Colorectal Cancer

300 enrolled

Colorectal Neoplasms

NCT07120451 2025-08-13

Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker

37 enrolled

Advanced Ovarian Cancer

NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

37 enrolled

mCRC

NCT07083375 2025-07-24

QL1706

56 enrolled

Extensive Small Cell Lung Cancer

NCT07001618 2025-07-23

IMMUNOLIFE2

162 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07070713 2025-07-17

Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC

44 enrolled

Metastatic Colorectal Cancer With Left-sided Primary Tumor

NCT07071844 2025-07-17

BETWEEN

162 enrolled

Neutropenia, Colorectal Neoplasms

NCT07045805 2025-07-01

Phase II Study of QL1706 Combined With Paclitaxel and Bevacizumab for Second-Line Immune Rechallenge in Gastric Cancer

66 enrolled

Stomach Neoplasms

NCT07021950 2025-06-15

AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer

130 enrolled

Colorectal Neoplasms

NCT07012798 2025-06-10

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

NCT07014215 2025-06-10

PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy

52 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07007728 2025-06-06

Iparomlimab/Tuvonralimab Combined With Bevacizumab and CAPEOX as Conversion Therapy for Colorectal Cancer Liver Metastasis

54 enrolled

Colorectal Neoplasms

NCT07009145 2025-06-06

QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC

22 enrolled

Colorectal Neoplasms

NCT06872606 2025-03-12

SCRIPBOT

33 enrolled

Rectal Neoplasms

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

28 enrolled

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06683703 2024-11-12

Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases

118 enrolled

Non-small Cell Lung Cancer Patients with Brain Metastases

NCT06650709 2024-10-23

NEOCATS

40 enrolled

Ovarian Neoplasms

NCT06537297 2024-09-20

Intrathecal Pemetrexed Combined With High-dose Furmonertinib and Beva for EGFR-m NSCLC With Leptomeningeal Metastases

Carcinoma, Non-Small-Cell Lung

NCT06539559 2024-08-06

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06530784 2024-07-31

Cryoablation Combined With PD-1 Antibody and Bevacizumab for Hepatocellular Carcinoma

36 enrolled

Carcinoma, Hepatocellular

NCT06513221 2024-07-22

A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab

100 enrolled

Colorectal Neoplasms

NCT06415851 2024-05-16

Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab

36 enrolled

Colorectal Neoplasms

NCT06408623 2024-05-10

Chidamide Combined With Sintilimab and Bevacizumab for the First-line Treatment of Advanced Liver Cancer

48 enrolled

Liver Neoplasms

NCT06364826 2024-04-15

Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma

Head & Neck

Nasopharyngeal Carcinoma

NCT06361979 2024-04-12

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Breasr Cancer

NCT06363552 2024-04-12

A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer

36 enrolled

Colorectal Neoplasms

NCT06192680 2024-01-18

Liposomal Irinotecan and Capecitabine Plus Bevacizumab as Second-line Therapy in Metastatic Colorectal Cancer

63 enrolled

Neoplasm Metastasis, Colorectal Neoplasms

NCT06210438 2024-01-18

SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases

24 enrolled

Brain Neoplasms

NCT06092242 2023-10-23

The Efficacy and Safety of TAS-102(Suyuan) Combined With Bevacizumab as First-line Therapy in Patients With Advanced Colorectal Cancer

50 enrolled

Colorectal Neoplasms

NCT05540275 2023-10-06

Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma

Glioblastoma

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

44 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06041490 2023-09-18

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

88 enrolled

GastrointestinalSarcoma

Carcinoma, Hepatocellular, Recurrence, Osteosarcoma

NCT05640726 2022-12-07

The First-line Treatment of RCLM With RAS Mutation Was Local Short-course Radiotherapy (SCRT) + PD-1+ Standard Therapy

Rectal Neoplasms

NCT05502991 2022-09-27

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma